Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00. Following the completion of the transaction, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,720,610.98. The trade was a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Andrew Guggenhime also recently made the following trade(s):
- On Friday, October 18th, Andrew Guggenhime sold 42,000 shares of Vaxcyte stock. The shares were sold at an average price of $115.39, for a total value of $4,846,380.00.
Vaxcyte Trading Up 0.5 %
Shares of NASDAQ:PCVX opened at $86.21 on Friday. Vaxcyte, Inc. has a 12 month low of $53.83 and a 12 month high of $121.06. The company has a market cap of $10.74 billion, a price-to-earnings ratio of -18.74 and a beta of 0.94. The company has a 50-day moving average price of $99.26 and a 200-day moving average price of $92.03.
Trump’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media | Ad
Discover the coin set to explode before 2025!
Trump could trigger THIS crypto coin…
YES, I WANT THE #1 CRYPTO NOW
Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter in the prior year, the business earned ($0.91) earnings per share. As a group, research analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.
Institutional Trading of Vaxcyte
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Riverview Trust Co bought a new position in shares of Vaxcyte during the third quarter valued at approximately $27,000. Blue Trust Inc. increased its position in Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after buying an additional 93 shares in the last quarter. Fifth Third Bancorp purchased a new position in Vaxcyte during the second quarter valued at $35,000. Meeder Asset Management Inc. boosted its holdings in Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock worth $80,000 after acquiring an additional 635 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. purchased a new stake in shares of Vaxcyte in the third quarter worth $92,000. 96.78% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research analysts have recently commented on the company. Leerink Partners upped their price target on Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a research report on Tuesday, September 3rd. BTIG Research lifted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday. They issued a "buy" rating and a $135.00 price target on the stock. Mizuho lifted their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $145.71.
Check Out Our Latest Research Report on PCVX
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
